• |
  • |
  • |
  • |
Donate

Product

Ototoxic Monitoring of 4000 Hz threshold in a Pediatric Population Diagnosed with Germ Cell Tumors in a Compressed Cisplatin Chemotherapy Trial

Center:
Fiscal Year:
2026
Contact Information:
Product Description:
&#8226; Germ cell tumor management commonly includes surgery and chemotherapy with cisplatin1 &#8226; 15% of patients treated with standard therapy (400mg/m2 cisplatin) develop hearing loss2 &#8226; Risk factors for cisplatin induced hearing loss: &#8226; Younger age (~<5 years) 2 &#8226; Higher fraction dosage2 &#8226; International guidelines recommend hearing monitoring before, during, and after treatment3 Compressed Chemotherapy Regime
Keyword(s):
Germcell tumors, Chemotherapy, Ototoxic
Product/Publication Type(s):
Conference presentations and posters presented
Target Audience:
Professionals, Students
Alternative Format:
Visual Format or Large Print
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A